High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria.
Mycoplasma genitalium
Azithromycin
Macrolide resistance
Men who have sex with men
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
22 Apr 2024
22 Apr 2024
Historique:
received:
10
11
2023
accepted:
04
04
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
22
4
2024
Statut:
aheadofprint
Résumé
Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, often harboring resistance-associated mutations to azithromycin (AZM). Global surveillance has been mandated to tackle the burden caused by MG, yet no data are available for Austria. Thus, we aimed to investigate the prevalence of MG, disease characteristics, and treatment outcomes at the largest Austrian HIV-and STI clinic. All MG test results at the Medical University of Vienna from 02/2019 to 03/2022 were evaluated. Azithromycin resistance testing was implemented in 03/2021. Among 2671 MG tests, 199 distinct and mostly asymptomatic (68%; 135/199) MG infections were identified, affecting 10% (178/1775) of all individuals. This study included 83% (1479/1775) men, 53% (940/1775) men who have sex with men (MSM), 31% (540/1754) HIV+, and 15% (267/1775) who were using HIV pre-exposure prophylaxis (PrEP). In logistic regression analysis, 'MSM' (aOR 2.55 (95% CI 1.65-3.92)), 'use of PrEP' (aOR 2.29 (95% CI 1.58-3.32)), and 'history of syphilis' (aOR 1.57 (95% CI 1.01-2.24) were independent predictors for MG infections. Eighty-nine percent (178/199) received treatment: 11% (21/178) doxycycline (2 weeks), 52% (92/178) AZM (5 days), and 37% ( 65/178) moxifloxacin (7-10 days) and 60% (106/178) had follow-up data available showing negative tests in 63% (5/8), 76% (44/58) and 85% (34/40), respectively. AZM resistance analysis was available for 57% (114/199)) and detected in 68% (78/114). Resistance-guided therapy achieved a cure in 87% (53/61), yet, empiric AZM-treatment (prior to 03/2021) cleared 68% (26/38). Mycoplasma genitalium was readily detected in this Austrian observational study, affected predominantly MSM and often presented as asymptomatic disease. We observed a worryingly high prevalence of AZM resistance mutations; however, empiric AZM treatment cleared twice as many MG infections as expected.
Sections du résumé
BACKGROUND
BACKGROUND
Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, often harboring resistance-associated mutations to azithromycin (AZM). Global surveillance has been mandated to tackle the burden caused by MG, yet no data are available for Austria. Thus, we aimed to investigate the prevalence of MG, disease characteristics, and treatment outcomes at the largest Austrian HIV-and STI clinic.
METHODS
METHODS
All MG test results at the Medical University of Vienna from 02/2019 to 03/2022 were evaluated. Azithromycin resistance testing was implemented in 03/2021.
RESULTS
RESULTS
Among 2671 MG tests, 199 distinct and mostly asymptomatic (68%; 135/199) MG infections were identified, affecting 10% (178/1775) of all individuals. This study included 83% (1479/1775) men, 53% (940/1775) men who have sex with men (MSM), 31% (540/1754) HIV+, and 15% (267/1775) who were using HIV pre-exposure prophylaxis (PrEP). In logistic regression analysis, 'MSM' (aOR 2.55 (95% CI 1.65-3.92)), 'use of PrEP' (aOR 2.29 (95% CI 1.58-3.32)), and 'history of syphilis' (aOR 1.57 (95% CI 1.01-2.24) were independent predictors for MG infections. Eighty-nine percent (178/199) received treatment: 11% (21/178) doxycycline (2 weeks), 52% (92/178) AZM (5 days), and 37% ( 65/178) moxifloxacin (7-10 days) and 60% (106/178) had follow-up data available showing negative tests in 63% (5/8), 76% (44/58) and 85% (34/40), respectively. AZM resistance analysis was available for 57% (114/199)) and detected in 68% (78/114). Resistance-guided therapy achieved a cure in 87% (53/61), yet, empiric AZM-treatment (prior to 03/2021) cleared 68% (26/38).
CONCLUSIONS
CONCLUSIONS
Mycoplasma genitalium was readily detected in this Austrian observational study, affected predominantly MSM and often presented as asymptomatic disease. We observed a worryingly high prevalence of AZM resistance mutations; however, empiric AZM treatment cleared twice as many MG infections as expected.
Identifiants
pubmed: 38649669
doi: 10.1007/s15010-024-02261-6
pii: 10.1007/s15010-024-02261-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clin Microbiol Rev. 2011;24:498–514. https://doi.org/10.1128/cmr.00006-11 .
doi: 10.1128/cmr.00006-11
pubmed: 21734246
pmcid: 3131060
Read TRH, Murray GL, Danielewski JA, Fairley CK, Doyle M, Worthington K, et al. Symptoms, Sites, and significance of Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis. 2019;25:719–27. https://doi.org/10.3201/eid2504.181258 .
doi: 10.3201/eid2504.181258
pubmed: 30882306
pmcid: 6433010
Ong JJ, Aung E, Read TRH, Fairley CK, Garland SM, Murray G, et al. Clinical characteristics of anorectal Mycoplasma genitalium infection and microbial cure in men who have sex with men. Sex Transm Dis. 2018;45:522–6. https://doi.org/10.1097/olq.0000000000000793 .
doi: 10.1097/olq.0000000000000793
pubmed: 29465653
Dumke R, Ziegler T, Abbasi-Boroudjeni N, Rust M, Glaunsinger T. Prevalence of macrolide- and fluoroquinolone-resistant Mycoplasma genitalium strains in clinical specimens from men who have sex with men of two sexually transmitted infection practices in Berlin, Germany. J Glob Antimicrob Resist. 2019;18:118–21. https://doi.org/10.1016/j.jgar.2019.06.015 .
doi: 10.1016/j.jgar.2019.06.015
pubmed: 31252154
Machalek DA, Tao Y, Shilling H, Jensen JS, Unemo M, Murray G, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis. 2020;20:1302–14. https://doi.org/10.1016/s1473-3099(20)30154-7 .
doi: 10.1016/s1473-3099(20)30154-7
pubmed: 32622378
Andersen B, Sokolowski I, Østergaard L, Kjølseth Møller J, Olesen F, Jensen JS. Mycoplasma genitalium: prevalence and behavioural risk factors in the general population. Sex Transm Infect. 2007;83:237–41. https://doi.org/10.1136/sti.2006.022970 .
doi: 10.1136/sti.2006.022970
pubmed: 17090566
Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, et al. Is Mycoplasma genitalium in women the “New Chlamydia?” A community-based prospective cohort study. Clin Infect Dis. 2010;51:1160–6. https://doi.org/10.1086/656739 .
doi: 10.1086/656739
pubmed: 20942656
Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58:631–7. https://doi.org/10.1093/cid/cit752 .
doi: 10.1093/cid/cit752
pubmed: 24280088
Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1917134. https://doi.org/10.1001/jamanetworkopen.2019.17134 .
doi: 10.1001/jamanetworkopen.2019.17134
pubmed: 31825501
pmcid: 6991203
Broad CE, Furegato M, Harrison MA, Pond MJ, Tan N, Okala S, et al. High prevalence of coinfection of azithromycin-resistant Mycoplasma genitalium with other STIs: a prospective observational study of London-based symptomatic and STI-contact clinic attendees. Sex Transm Infect. 2021;97:63–8. https://doi.org/10.1136/sextrans-2019-054356 .
doi: 10.1136/sextrans-2019-054356
pubmed: 32393529
Jansen K, Steffen G, Potthoff A, Schuppe AK, Beer D, Jessen H, et al. STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. BMC Infect Dis. 2020;20:110. https://doi.org/10.1186/s12879-020-4831-4 .
doi: 10.1186/s12879-020-4831-4
pubmed: 32033533
pmcid: 7007644
Ring A, Balakrishna S, Imkamp F, Burkard S, Triet F, Brunschweiler F, et al. High rates of asymptomatic Mycoplasma genitalium infections with high proportion of genotypic resistance to first-line macrolide treatment among men who have sex with men enrolled in the Zurich Primary HIV Infection Study. Open Forum Infect Dis. 2022;9:ofac217. https://doi.org/10.1093/ofid/ofac217 .
doi: 10.1093/ofid/ofac217
pubmed: 35783686
pmcid: 9246285
Pitt R, Boampong D, Day M, Jensen JS, Cole M. Challenges of in vitro propagation and antimicrobial susceptibility testing of Mycoplasma genitalium. J Antimicrob Chemother. 2022;77:2901–7. https://doi.org/10.1093/jac/dkac281 .
doi: 10.1093/jac/dkac281
pubmed: 35979812
Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. 2021 European guideline on the management of Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2022;36:641–50. https://doi.org/10.1111/jdv.17972 .
doi: 10.1111/jdv.17972
pubmed: 35182080
Doyle M, Vodstrcil LA, Plummer EL, Aguirre I, Fairley CK, Bradshaw CS. nonquinolone options for the treatment of Mycoplasma genitalium in the era of increased resistance. Open Forum Infect Dis. 2020;7:ofaa291. https://doi.org/10.1093/ofid/ofaa291 .
doi: 10.1093/ofid/ofaa291
pubmed: 32782911
pmcid: 7408185
Berçot B, Charreau I, Clotilde R, Delaugerre C, Chidiac C, Pialoux G, et al. High prevalence and high rate of antibiotic resistance of Mycoplasma genitalium infections in men who have sex with men. A sub-study of the ANRS ipergay PrEP trial. Clin Infect Dis. 2020;73:e2127–33. https://doi.org/10.1093/cid/ciaa1832 .
doi: 10.1093/cid/ciaa1832
Van Praet JT, Steyaert S, Vandecasteele S, Van Den Bergh B, Mahieu H, De Buyser S, et al. Mycoplasma genitalium acquisition and macrolide resistance after initiation of HIV pre-exposure prophylaxis in men who have sex with men. Sex Transm Infect. 2020;96:396–8. https://doi.org/10.1136/sextrans-2019-054335 .
doi: 10.1136/sextrans-2019-054335
pubmed: 31896737
De Baetselier I, Vuylsteke B, Reyniers T, Smet H, Van den Bossche D, Kenyon C, et al. Worryingly high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium among men who have sex with men with recurrent sexually transmitted infections. Int J STD AIDS. 2022;33:385–90. https://doi.org/10.1177/09564624211070704 .
doi: 10.1177/09564624211070704
pubmed: 35094623
Ahaus P, Schmidt AJ, Skaletz-Rorowski A, Uhrmacher M, Serova K, Kayser A, et al. Changes in the user profiles of HIV pre-exposure prophylaxis (PrEP) before and after PrEP reimbursement. J Infect Public Health. 2022;15:955–60. https://doi.org/10.1016/j.jiph.2022.07.012 .
doi: 10.1016/j.jiph.2022.07.012
pubmed: 35926293
Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1–187. https://doi.org/10.15585/mmwr.rr7004a1 .
doi: 10.15585/mmwr.rr7004a1
pubmed: 34292926
pmcid: 8344968
Soni S, Horner P, Rayment M, Pinto-Sander N, Naous N, Parkhouse A, et al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018). Int J STD AIDS. 2019;30:938–50. https://doi.org/10.1177/0956462419825948 .
doi: 10.1177/0956462419825948
pubmed: 31280688
Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016;30:1650–6. https://doi.org/10.1111/jdv.13849 .
doi: 10.1111/jdv.13849
pubmed: 27505296
Fernández-Huerta M, Barberá MJ, Esperalba J, Fernandez-Naval C, Vall-Mayans M, Arando M, et al. Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study. Sex Transm Infect. 2020;96:300–5. https://doi.org/10.1136/sextrans-2019-054124 .
doi: 10.1136/sextrans-2019-054124
pubmed: 31451540
Latimer RL, Shilling HS, Vodstrcil LA, Machalek DA, Fairley CK, Chow EPF, et al. Prevalence of Mycoplasma genitalium by anatomical site in men who have sex with men: a systematic review and meta-analysis. Sex Transm Infect. 2020;96:563–70. https://doi.org/10.1136/sextrans-2019-054310 .
doi: 10.1136/sextrans-2019-054310
pubmed: 32341023
Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis. 2017;65:712–8. https://doi.org/10.1093/cid/cix439 .
doi: 10.1093/cid/cix439
pubmed: 28505240
pmcid: 5848234
Buyze J, Vanden Berghe W, Hens N, Kenyon C. Current levels of gonorrhoea screening in MSM in Belgium may have little effect on prevalence: a modelling study. Epidemiol Infect. 2018;146:333–8. https://doi.org/10.1017/s0950268818000092 .
doi: 10.1017/s0950268818000092
pubmed: 29386078
Tsoumanis A, Hens N, Kenyon CR. Is screening for chlamydia and gonorrhea in men who have sex with men associated with reduction of the prevalence of these infections? A systematic review of observational studies. Sex Transm Dis. 2018;45:615–22. https://doi.org/10.1097/olq.0000000000000824 .
doi: 10.1097/olq.0000000000000824
pubmed: 29485537
Kenyon C. We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in preexposure prophylaxis cohorts. AIDS. 2019;33:155–7. https://doi.org/10.1097/qad.0000000000002020 .
doi: 10.1097/qad.0000000000002020
pubmed: 30234609
Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13. https://doi.org/10.1186/1471-2334-14-13 .
doi: 10.1186/1471-2334-14-13
pubmed: 24405683
pmcid: 3897982
Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60:1228–36. https://doi.org/10.1093/cid/ciu1162 .
doi: 10.1093/cid/ciu1162
pubmed: 25537875
Read TRH, Jensen JS, Fairley CK, Grant M, Danielewski JA, Su J, et al. Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection. Emerg Infect Dis. 2018;24:328–35. https://doi.org/10.3201/eid2402.170902 .
doi: 10.3201/eid2402.170902
pubmed: 29350154
pmcid: 5782881
European Center for Disease Control and Prevention. Gonococcal antimicrobial susceptibility surveillance in the EU/EEA: summary of results for 2019. Stockholm: ECDC; 2021.
Dukers-Muijrers N, Wolffs PFG, De Vries H, Götz HM, Heijman T, Bruisten S, et al. Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal chlamydia trachomatis infections in women: a multicenter observational study (FemCure). Clin Infect Dis. 2019;69:1946–54. https://doi.org/10.1093/cid/ciz050 .
doi: 10.1093/cid/ciz050
pubmed: 30689759
pmcid: 6853690
Lau A, Kong FYS, Fairley CK, Templeton DJ, Amin J, Phillips S, et al. Azithromycin or doxycycline for asymptomatic rectal Chlamydia trachomatis. N Engl J Med. 2021;384:2418–27. https://doi.org/10.1056/NEJMoa2031631 .
doi: 10.1056/NEJMoa2031631
pubmed: 34161706
Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020. https://doi.org/10.1177/0956462420949126 .
doi: 10.1177/0956462420949126
pubmed: 33323071
Geusau A, Chromy D, Heissenberger D, Lippert K, Eder C, Heger F, et al. Resistance profiles of Neisseria gonorrhoeae isolates in Vienna, Austria: a phenotypic and genetic characterization from 2013 to 2020. Int J Antimicrob Agents. 2022;60: 106656. https://doi.org/10.1016/j.ijantimicag.2022.106656 .
doi: 10.1016/j.ijantimicag.2022.106656
pubmed: 35988663
Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47:1546–53. https://doi.org/10.1086/593188 .
doi: 10.1086/593188
pubmed: 18990060
De Baetselier I, Kenyon C, Vanden Berghe W, Smet H, Wouters K, Van den Bossche D, et al. An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: results from samples collected between 2015 and 2018. Sex Transm Infect. 2020;97:297–303. https://doi.org/10.1136/sextrans-2020-054511 .
doi: 10.1136/sextrans-2020-054511
pubmed: 32769204
Nijhuis RH, Severs TT, Van der Vegt DS, Van Zwet AA, Kusters JG. High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment. J Antimicrob Chemother. 2015;70:2515–8. https://doi.org/10.1093/jac/dkv136 .
doi: 10.1093/jac/dkv136
pubmed: 25995292